Blood Glycan Biomarkers in Women With Stage IV Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT00897962
- Lead Sponsor
- University of California, Davis
- Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
- Detailed Description
OBJECTIVES:
* To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness.
* To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment.
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 163
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness up to 18 months
- Secondary Outcome Measures
Name Time Method Predictability of serial serum biomarkers in determining disease response and/or progression Up to 18 months
Trial Locations
- Locations (1)
University of California Davis Cancer Center
🇺🇸Sacramento, California, United States
University of California Davis Cancer Center🇺🇸Sacramento, California, United States